CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers

Written by Rachel Swansburg

GO BACK TO PRESS RELEASES & MEDIA

Presentation

April 27, 2025

CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers

Rachel Swansburg
Previous

Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting
Next

CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01